Juvenile Myelomonocytic Leukemia (JMML)

Juvenile Myelomonocytic Leukemia (JMML) is a rare pediatric malignancy classified as a myelodysplastic/myeloproliferative overlap neoplasm. It is characterized by the uncontrolled proliferation of monocytes and granulocytes, arising from mutations in the RAS signal-transduction pathway. JMML predominantly affects young children under the age of four, with a slight male predominance.

The disease progresses rapidly and rarely resolves spontaneously — except in a small subset of infants with Noonan syndrome-associated PTPN11 germline mutations, where a watch-and-wait approach may be appropriate. In all other cases, allogeneic hematopoietic stem cell transplantation (HSCT) is required for a chance at long-term disease control.

Accurate molecular profiling at diagnosis is essential, as the specific mutation (NF1, NRAS, KRAS, PTPN11, or CBL) influences prognosis, treatment strategy, and eligibility for clinical trials. Enrolling in a specialized pediatric program with experience in JMML is strongly recommended, as management decisions are nuanced and best guided by expert multidisciplinary teams.

JMML is classified according to the underlying somatic or germline mutation in the RAS/MAPK pathway, which defines the biological subgroup. Identifying the specific mutation is essential for prognosis and for guiding enrollment into mutation-specific trials.

JMML typically presents in young children with a combination of systemic, hematologic, and organ-related symptoms. Because many of these features can mimic benign viral infections or inflammatory conditions, a high index of suspicion is needed, particularly in children with an underlying RASopathy.

JMML arises from mutations in genes encoding components of the RAS/MAPK intracellular signaling pathway. These mutations lead to constitutive activation of RAS, driving uncontrolled proliferation of the myelomonocytic lineage. In most cases the mutation is acquired somatically; in a significant minority it arises on a germline predisposition background.

JMML diagnosis requires integration of clinical, morphological, cytogenetic, and molecular data. The WHO 2022 classification requires monocytosis, absence of the BCR-ABL1 fusion (Philadelphia chromosome), and confirmation of a somatic RAS-pathway mutation or fulfillment of specific clinical criteria. Expert hematopathology review is strongly recommended.

JMML is not staged using conventional TNM or Ann Arbor systems. Risk stratification uses clinical, hematologic, and molecular parameters to identify children at highest risk for post-transplant relapse and to guide conditioning and donor selection decisions.

Allogeneic hematopoietic stem cell transplantation is the only established treatment with curative potential in JMML. Pre-transplant disease management aims to control disease burden, and post-transplant strategies focus on preventing relapse. Treatment is highly individualized and should be conducted in a specialized pediatric transplant program.

Given the high post-transplant relapse rate in JMML, several novel agents are under active investigation, particularly those targeting RAS-pathway signaling. Access to clinical trials through specialized centers offers children with JMML an opportunity to receive investigational therapies beyond the current standard of care.

Molecular characterization of the RAS-pathway mutation is fundamental to diagnosis, risk stratification, and treatment selection in JMML. Biomarker testing should be performed at diagnosis, at transplant, and at relapse to guide management decisions.

JMML is among the rarest and most complex pediatric leukemias. Given its molecular heterogeneity, the nuanced decision-making around transplant timing and donor selection, and the high relapse rate, second opinions from additional specialist centers are strongly encouraged — particularly when initial diagnostic or treatment recommendations are uncertain.

Outcomes in JMML depend heavily on the underlying molecular subtype, age at diagnosis, pre-transplant disease burden, and availability of a well-matched donor for HSCT. Post-transplant relapse remains the leading cause of treatment failure, and long-term follow-up is essential to monitor for late effects of conditioning therapy and GVHD.

Comprehensive supportive care is integral to the management of children with JMML throughout diagnosis, transplant, and recovery. Given the very young age of most affected children, family-centered care and psychosocial support are critical components of the treatment plan.